See more : Propellus Inc. (PRPS) Income Statement Analysis – Financial Results
Complete financial analysis of Mind Medicine (MindMed) Inc. (MNMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mind Medicine (MindMed) Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Jiangsu Baichuan High-Tech New Materials Co., Ltd (002455.SZ) Income Statement Analysis – Financial Results
- China Resources Power Holdings Company Limited (CRPJY) Income Statement Analysis – Financial Results
- Evolis SA (ALTVO.PA) Income Statement Analysis – Financial Results
- Implanet S.A. (ALIMP.PA) Income Statement Analysis – Financial Results
- Solvar Limited (SVR.AX) Income Statement Analysis – Financial Results
Mind Medicine (MindMed) Inc. (MNMD)
About Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.16M | 3.22M | 2.62M | 0.00 | 6.68K | 6.68K | 5.50K | 0.00 | 0.00 |
| Gross Profit | -3.16M | -3.22M | -2.62M | 0.00 | -6.68K | -6.68K | -5.50K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 48.96M | 36.17M | 34.79M | 18.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 41.74M | 30.16M | 59.07M | 14.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 41.74M | 30.16M | 59.07M | 14.40M | 461.50K | 855.26K | 1.23M | 111.25K | 94.55K |
| Other Expenses | 0.00 | 2.00K | 106.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 93.87M | 66.33M | 93.85M | 33.03M | 461.50K | 855.26K | 1.23M | 111.25K | 94.55K |
| Cost & Expenses | 93.87M | 66.33M | 93.85M | 33.03M | 468.18K | 861.94K | 1.24M | 111.25K | 94.55K |
| Interest Income | 4.66M | 1.50M | 0.00 | 0.00 | 0.00 | 4.00K | 8.40K | 1.20K | 1.90K |
| Interest Expense | 0.00 | 1.50M | 359.00K | 164.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.16M | 3.22M | 2.62M | 206.30K | 6.68K | 6.68K | 5.50K | 0.00 | 0.39 |
| EBITDA | -92.57M | -53.57M | -91.22M | -33.77M | -1.11M | -851.26K | -1.51M | -111.25K | -92.66K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -93.87M | -66.33M | -96.36M | -33.03M | -468.18K | -861.94K | -1.24M | -111.25K | -94.55K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.87M | 9.54M | -339.00K | -907.00K | -647.63K | 4.00K | 8.40K | -68.65K | 1.89K |
| Income Before Tax | -95.73M | -56.80M | -94.19M | -33.94M | -1.12M | -857.94K | -1.23M | -179.90K | -92.66K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -9.54M | -1.16M | 164.00K | -3.69 | -1.91 | -1.70 | 0.00 | -0.39 |
| Net Income | -95.73M | -47.26M | -93.04M | -34.10M | -1.12M | -857.94K | -1.23M | -179.90K | -92.66K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.44 | -1.53 | -3.40 | -1.92 | -2.94 | -2.74 | -4.85 | -2.24 | -1.17 |
| EPS Diluted | -2.44 | -1.53 | -3.40 | -1.92 | -2.94 | -2.74 | -4.85 | -2.24 | -1.17 |
| Weighted Avg Shares Out | 39.16M | 30.86M | 27.38M | 17.75M | 379.41K | 312.55K | 252.82K | 80.42K | 79.00K |
| Weighted Avg Shares Out (Dil) | 39.16M | 30.86M | 27.38M | 17.75M | 379.41K | 312.55K | 252.82K | 80.42K | 79.00K |
Are Medical Stocks Lagging Mind Medicine MindMed (MNMD) This Year?
Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
MindMed to Participate in June Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will participate in the...
The Time Traveler's Portfolio: 3 Stocks to Buy Now for Massive Returns by 2034
Imagine you could go back in time to find last decade's long-term stocks to buy. Nvidia (NASDAQ: NVDA ) returned nearly 20,000% growth since 2014.
Psychedelics Closer To Commercialization; Compass Far And Away The Leader
Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies through private placements.
Top Russell 2000 Picks: 3 Small-Cap Stocks to Scoop Up This May
The stock market continues to question whether a large cap dominance — especially that from The Magnificent Seven — is indeed the best way to invest. While investing in large cap firms is undoubtedly a good strategy, there are plenty...
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
Biotech breakthrough stocks, along with the sector overall, faced significant challenges over the past two years, with venture capital drying up, shifts in the post-pandemic healthcare landscape and tighter regulatory conditions squeezing already-thin margins. However, 2024 may herald a resurgence...
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented data from MMED008, its Phase 2b study of MM120 (lysergide d-tartrate)...
The Top 3 Small-Cap Stocks to Buy in April 2024
Higher interest rates, pricier debt and an overemphasis on mega-caps over the past year mean that top small-cap stocks have played second fiddle to big-name giants like Nvidia (NASDAQ: NVDA ). But tides seem to be turning as investors increasingly...
MindMed to Present at Upcoming May Medical Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study...
This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher
Mind Medicine has an exciting treatment option for generalized anxiety disorder -- MM120. In clinical trials, MM120 reduced anxiety in patients after just a single dose.
Source: https://incomestatements.info
Category: Stock Reports